Biogen Inc. Initiates Phase 3 Study for Primary Membranous Nephropathy Treatment

Cambridge, Mass., June 30, 2025 — Biogen Inc. (Nasdaq: BIIB), a leading health care biotechnology company, has announced the initiation of a global Phase 3 clinical study named PROMINENT. This study aims to evaluate the efficacy and safety of felzartamab, an investigational anti-CD38 monoclonal antibody, in comparison to tacrolimus for the treatment of primary membranous nephropathy (PMN). PMN is a rare, immune-mediated kidney disease with an estimated prevalence of approximately 36,000 patients in the United States.

The PROMINENT study is designed to enroll around 180 adults diagnosed with PMN and is expected to conclude in 2029. Felzartamab is being explored as a potentially differentiated therapeutic candidate for a broad range of immune-mediated diseases, including PMN, for which there are currently no specifically approved therapies.

Regenerative Medicine Market Forecast

In related industry news, a comprehensive market research report by Meticulous Market Research Pvt. Ltd. projects the regenerative medicine market to reach $45.66 billion by 2032. This represents a significant growth from an estimated $11.33 billion in 2025, with a compound annual growth rate (CAGR) of 22.0% during the forecast period. The growth is attributed to increasing drug approvals, advancements in regenerative medicine technologies, the rising incidence of chronic health conditions, and expanding therapeutic applications.

INmune Bio’s Alzheimer’s Drug Trial Results

In other biotechnology news, INmune Bio’s experimental Alzheimer’s drug, XPro, failed to meet its mid-stage study goals. The drug, designed to inhibit inflammatory signals associated with tumor necrosis factor, did not show improvement in cognitive functions in patients with early-stage Alzheimer’s disease. The study involved 208 patients with mild Alzheimer’s or mild cognitive impairment, who were administered weekly subcutaneous injections of XPro or a placebo over 24 weeks. Following the announcement, INmune Bio’s shares dropped approximately 60% to a record low.

Biogen Inc., headquartered in Cambridge, Massachusetts, continues to focus on developing therapies in neurology, oncology, and immunology, targeting diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, Crohn’s disease, and psoriasis. For more information, visit Biogen’s website .